Qurient announced the first patient dosed in a Phase 2 study of mocaciclib (Q901) for CDK4/6 inhibitor-resistant HR+ breast ...
The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...
The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.
Your doctor will check your blood at regular intervals during treatment. When you start taking these medications, your doctor may do blood tests once every two weeks. After the first couple of visits, ...
Scientists have discovered that a rare “mirror-image” version of the amino acid cysteine can dramatically slow the growth of certain cancers while leaving healthy cells largely untouched. Unlike most ...
Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results